Central anandamide deficiency predicts stress-induced anxiety: Behavioral reversal through endocannabinoid augmentation

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Bluett, R J ^a   Gamble George, J C ^a   Hermanson, D J ^b   Hartley, N D ^a   Marnett, L J ^b   Patel, S ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ANANDAMIDE DEGRADING ENZYME; CANNABINOID RECEPTOR; ENDOCANNABINOID; ENZYME; FATTY ACID AMIDASE; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; CANNABINOID 1 RECEPTOR; FATTY ACID AMIDASE INHIBITOR; PF 3845; RIMONABANT; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; FATTY-ACID AMIDE HYDROLASE;

ACUTE STRESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FOOTSHOCK; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; STRESS; CORRELATION ANALYSIS; EXPERIMENTAL ANXIETY TEST; LATENT PERIOD; LIGHT-DARK TEST; NOVELTY INDUCED HYPOPHAGIA ASSAY; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; ANXIETY; COMPLICATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ETIOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MENTAL STRESS; METABOLISM; PHYSIOLOGY;

AMIDOHYDROLASES; ANIMALS; ANXIETY; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; MALE; MICE; MICE, INBRED ICR; POLYUNSATURATED ALKAMIDES; STRESS, PSYCHOLOGICAL;

EID: 84903752444     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.53     Document Type: Article

References (32)

1. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-389. (Pubitemid 36877077)
2. Hunter RG, McEwen BS. Stress and anxiety across the lifespan: structural plasticity and epigenetic regulation. Epigenomics 2013; 5: 177-194.
3. Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 2013; 12: 667-687.
4. Gamble-George JC, Conger JR, Hartley ND, Gupta P, Sumislawski JJ, Patel S. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology 2013; 228: 401-409.
5. Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ et al. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat Neurosci 2013; 16: 1291-1298.
6. Patel S, Hillard CJ. Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci 2009; 1: 347-371.
7. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B et al. Convergent translational evidence of a role for anandamide in amygdalamediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013; 18: 813-823.
8. Bowles NP, Hill MN, Bhagat SM, Karatsoreos IN, Hillard CJ, McEwen BS. Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice. Neuroscience 2012; 204: 83-89.
9. Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology 2010; 151: 4811-4819.
10. Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neurosci Biobehav Rev 2008; 32: 1152-1160.
11. Wang W, Sun D, Pan B, Roberts CJ, Sun X, Hillard CJ et al. Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress. Neuropsychopharmacology 2010; 35: 2249-2261.
12. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81. (Pubitemid 36098263)
13. Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009; 23: 133-144.
14. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337-1343. (Pubitemid 35285983)
15. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617. (Pubitemid 35356203)
16. Shrivastava A, Johnston M, Terpstra K, Bureau Y. Cannabis and psychosis: Neurobiology. Indian J Psychiatry 2014; 56: 8-16.
17. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 2011; 98: 21-27.
18. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid- degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008; 54: 141-150. (Pubitemid 350299416)
19. Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 2013; 18: 1125-1135.
20. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A et al. Antidepressantlike activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007; 62: 1103-1110. (Pubitemid 350029716)
21. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 2013; 34: 637-644.
22. Patel S, Roelke CT, Rademacher DJ, Hillard CJ. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 2005; 21: 1057-1069. (Pubitemid 40461057)
23. Rademacher DJ, Meier SE, Shi L, Ho WS, Jarrahian A, Hillard CJ. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008; 54: 108-116. (Pubitemid 350299407)
24. Kingsley PJ, Marnett LJ. Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. Anal Biochem 2003; 314: 8-15. (Pubitemid 36299014)
25. Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, Panlilio LV et al. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology 2009; 204: 607-616.
26. Sciolino NR, Zhou W, Hohmann AG. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-Arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 2011; 64: 226-234.
27. Rossi S, DeChiara V, Musella A, Sacchetti L, Cantarella C, Castelli M et al. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol Pharmacol 2010; 78: 260-268.
28. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006; 318: 304-311.
29. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-515. (Pubitemid 40271153)
30. Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H. Acute stress increases circulating anandamide and other N-Acylethanolamines in healthy humans. Neuropsychopharmacology 2012; 37: 2416-2427.
31. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: A preliminary report. Pharmacopsychiatry 2008; 41: 48-53. (Pubitemid 351427522)
32. Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS et al. Reductions in circulating endocannabinoid levels in individuals with post-Traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology 2013; 38: 2952-2961.